Management of small cell cancer of the lung.

摘要: Small cell lung cancer (SCLC) accounts for 20% to 25% of bronchogenic carcinoma cases. Combination chemotherapy offers the best chance improved survival. Cisplatin plus etoposide appears be most reasonable choice first line therapy. Increasing dose intensity, although sometimes associated with higher response rates, does not appear significantly improve Concurrent thoracic radiotherapy administered early in course confers a survival advantage over alone limited-stage SCLC. Prophylactic cranial irradiation reduces central nervous system recurrences minimal long-term sequelae and Several new cytotoxic agents are active These include gemcitabine, paclitaxel, docetaxel, topotecan, irinotecan, JM216. Novel approaches being investigated antibodies factors expressed by SCLC cells targeting angiogenesis, cycle regulation, cell-signaling pathways.